ASX:OSL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. More Details


Snowflake Analysis

Excellent balance sheet with concerning outlook.

Share Price & News

How has OncoSil Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

OSL

-2.5%

AU Life Sciences

-0.3%

AU Market


1 Year Return

103.1%

OSL

44.9%

AU Life Sciences

-11.1%

AU Market

Return vs Industry: OSL exceeded the Australian Life Sciences industry which returned 44.9% over the past year.

Return vs Market: OSL exceeded the Australian Market which returned -11.1% over the past year.


Shareholder returns

OSLIndustryMarket
7 Day0%-2.5%-0.3%
30 Day18.2%-14.2%-4.2%
90 Day4.0%11.5%1.6%
1 Year107.2%103.1%49.1%44.9%-7.8%-11.1%
3 Year15.3%13.0%18.7%8.5%17.1%2.1%
5 Year-24.2%-25.7%-20.3%-36.9%43.1%13.0%

Price Volatility Vs. Market

How volatile is OncoSil Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OncoSil Medical undervalued compared to its fair value and its price relative to the market?

4.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OSL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OSL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OSL is unprofitable, so we can't compare its PE Ratio to the XX Life Sciences industry average.

PE vs Market: OSL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSL is overvalued based on its PB Ratio (4.9x) compared to the AU Life Sciences industry average (4.6x).


Next Steps

Future Growth

How is OncoSil Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSL's revenue (11.8% per year) is forecast to grow faster than the Australian market (4.3% per year).

High Growth Revenue: OSL's revenue (11.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has OncoSil Medical performed over the past 5 years?

-13.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSL is currently unprofitable.

Growing Profit Margin: OSL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.

Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (17.7%).


Return on Equity

High ROE: OSL has a negative Return on Equity (-19.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is OncoSil Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OSL's short term assets (A$23.9M) exceed its short term liabilities (A$2.2M).

Long Term Liabilities: OSL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OSL's debt to equity ratio (0.03%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OSL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: OSL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 12.2% each year


Next Steps

Dividend

What is OncoSil Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Daniel Kenny

5.67yrs

Tenure

Mr. Daniel Kenny has been the Chief Executive Officer of Oncosil Medical Limited since January 5, 2015 and serves as its Managing Director. He has over 35 years’ experience in the Global Pharmaceutical an ...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD353.41K) is about average for companies of similar size in the Australian market ($USD279.49K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Kenny
CEO, MD & Executive Director5.67yrsno data2.46%
A$ 2.6m
Karl Pechmann
Chief Financial Officer0.50yrAU$305.31k0.020%
A$ 21.5k
Michael Warrener
Global Sales & Marketing Director4.25yrsno data0.77%
A$ 831.2k
David James
Global Head of Manufacturing Operations4.92yrsno data0.77%
A$ 831.0k
Charles Rowland
President of US Operationsno datano datano data
Nigel Lange
President of EMEA0.33yrno datano data

4.3yrs

Average Tenure

Experienced Management: OSL's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Kenny
CEO, MD & Executive Director5.67yrsno data2.46%
A$ 2.6m
Christopher Roberts
Independent Non-Executive Chairman3.33yrsno data1.53%
A$ 1.6m
Roger Aston
Non-Executive Director7.5yrsAU$58.93k1.59%
A$ 1.7m
Pierce Chow
Member of Pancreatic Cancer Clinical Advisory Boardno datano datano data
Martin Cross
Independent Non-Executive Director3.58yrsAU$80.00k0.33%
A$ 354.5k
Michael John Bassett
Non-Executive Director1.75yrsAU$80.00k0.13%
A$ 145.1k
Joseph Herman
Member of Pancreatic Cancer Clinical Advisory Boardno datano datano data
Stephen Clarke
Member of Pancreatic Cancer Clinical Advisory Boardno datano datano data
Richard Epstein
Member of Pancreatic Cancer Clinical Advisory Boardno datano datano data
Dale Bailey
Member of Pancreatic Cancer Clinical Advisory Boardno datano datano data

3.6yrs

Average Tenure

Experienced Board: OSL's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.4%.


Top Shareholders

Company Information

OncoSil Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OncoSil Medical Limited
  • Ticker: OSL
  • Exchange: ASX
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$107.718m
  • Shares outstanding: 828.60m
  • Website: https://www.oncosil.com.au

Location

  • OncoSil Medical Limited
  • 50 Berry Street
  • Suite 402
  • North Sydney
  • New South Wales
  • 2060
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2005
N6ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2005
OSLCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2005

Biography

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 20:50
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.